Inhibition of TMEM16A by Natural Product Silibinin: Potential Lead Compounds for Treatment of Lung Adenocarcinoma
Background: Effective anticancer therapy can be achieved by identifying novel tumor-specific drug targets and screening of new drugs. Recently, TMEM16A has been identified to be overexpressed in lung adenocarcinoma, and inhibitors of TMEM16A showed obvious antitumor efficacy.Methods: YFP fluorescenc...
Main Authors: | Shuai Guo, Xue Bai, Yufei Liu, Sai Shi, Xuzhao Wang, Yong Zhan, Xianjiang Kang, Yafei Chen, Hailong An |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2021-04-01
|
Series: | Frontiers in Pharmacology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fphar.2021.643489/full |
Similar Items
-
TMEM16A, a Homoharringtonine Receptor, as a Potential Endogenic Target for Lung Cancer Treatment
by: Shuai Guo, et al.
Published: (2021-10-01) -
Paneth Cell Secretion in vivo Requires Expression of Tmem16a and Tmem16f
by: Rainer Schreiber, et al.
Published: (2022-01-01) -
Divalent Cation Modulation of Ion Permeation in TMEM16 Proteins
by: Dung M. Nguyen, et al.
Published: (2021-02-01) -
Generation of human TMEM16F-specific affibodies using purified TMEM16F
by: Eunyoung Kim, et al.
Published: (2024-01-01) -
Pharmacological Inhibition and Activation of the Ca<sup>2+</sup> Activated Cl<sup>−</sup> Channel TMEM16A
by: Raquel Centeio, et al.
Published: (2020-04-01)